

Myths vs. Facts: Pharmacy-Based “Test and Treat”

Myth: Pharmacists are not sufficiently trained to administer point-of-care tests, conduct patient assessments, nor initiate treatment for common health conditions.

Fact: Pharmacists are clinically trained healthcare professionals who, in addition to serving as medication experts, are educated to order and administer tests and manage treatments for common conditions.

Since 2004, all entry-level pharmacists graduate with a Doctor of Pharmacy degree, completing a robust curriculum that prepares pharmacists to provide direct patient care, clinical assessments, and evidence-based treatment and management of a wide variety of health conditions.ⁱ In fact, more than half of the national licensing exam for entry-level pharmacists is focused on obtaining, interpreting, and assessing medical data and patient information, and developing and managing treatment plans.ⁱⁱ Additionally, point-of-care tests are often used in both medical offices and pharmacies, and these tests, by definition, are so simple that there is little risk of error.ⁱⁱⁱ In initiating any treatments based on test results, pharmacists strictly adhere to evidence-based protocols that reflect the latest clinical guidelines, and as medication experts, are well prepared to manage drug therapy, including any drug interactions.

Myth: Pharmacist testing and treatment services have not been previously studied or implemented.

Fact: For more than a decade, pharmacists in the United States have increasingly provided testing and treatment services.^{iv,v}

In fact, the use of CLIA-waived tests in pharmacies has grown by 140% since 2019, given the essential need for more accessible testing services during the recent public health emergency where pharmacies provided more than 42 million COVID-19 tests.^{vi,vii} Further, a wide array of pharmacy-based testing and treatment or referral services have been proven safe and effective, including for influenza, strep throat, blood glucose, HIV, hepatitis C, latent tuberculosis, and more.^{viii,ix,x,xi} For example, a study analyzing community pharmacist testing and treatment services tested 273 patients for strep throat, of which 46 patients tested positive and received the appropriate treatment. At follow-up, almost 94% of patients that tested positive reported feeling better, and patients that reported feeling worse were referred to additional care. Also, of those tested, more than 43% did not have a primary care provider.^{xii}

Myth: Allowing pharmacists to initiate treatment based on test results could lead to misdiagnosis and mistreatment.

Fact: Pharmacists administer the same high-quality tests used across healthcare settings with robust quality control measures, low user error, and simple-to-read results.ⁱⁱⁱ

Pharmacists closely follow the testing manufacturer's instructions for administering tests and reading the results. When initiating treatment based on test results, pharmacists adhere to current, evidence-based clinical guidelines that reflect the most appropriate treatment. In fact, research indicates that pharmacists more strictly follow clinical prescribing guidelines compared to other healthcare providers.^{xiii}

In addition to performing a test, pharmacists often conduct other assessments to ensure the most appropriate treatment or referral is provided. These assessments may include a patient interview about their symptoms, a brief physical exam, or a vital signs check. In fact, when a pharmacist's assessment indicates that something more serious may be going on, the pharmacist will refer the patient to higher levels of care, such as the emergency room or their medical provider, as appropriate.

Myth: The public would not seek testing and treatment of common health conditions at pharmacies.

Fact: The public has become even more accustomed to receiving clinical care from their local pharmacist in recent years, including testing and treatment services.

In fact, 58% of Americans are likely to visit a pharmacy first when faced with a non-emergency medical issue and 81% say they trust a pharmacist to diagnose minor illnesses and prescribe medications to treat them.^{xiv} Also, more than 70% of Americans believe that it is important for pharmacists to test and treat common illnesses and minor conditions like flu and strep throat.^{xv} For example, in a study of people who received testing and treatment services from a pharmacist, 98% were satisfied with the care provided and stated they would use it again.^{xvi} Research indicates that when pharmacists offer testing and treatment, over a third of people who utilize the service may not have access to a primary care provider, and almost 40% visit the pharmacy outside of usual medical office hours.^{xvii}

Today, more than 100 million Americans do not have a primary care provider, nearly a third of the U.S. population. Without sufficient access to primary care, people may forgo evaluation and treatment for common conditions, which threatens the health of communities, and ultimately contributes to worse health outcomes and higher healthcare costs. Pharmacists providing testing and treatment services can help extend the reach of primary care to close access gaps, while also supporting effective referrals and linkages to primary care and follow-up.

Myth: Pharmacists are not as accessible as other healthcare providers for testing and treatment services.

Fact: With 60,000+ community-based pharmacies across the country, nearly half of Americans live within 1 mile of pharmacy, while 89% live within 5 miles, and 97% live within 10 miles.^{xviii}

Pharmacies frequently offer extended hours beyond the typical nine-to-five weekday schedule, providing additional care opportunities after work and school hours. In fact, pharmacies are visited 10 times more frequently than the average patient's primary care provider.^{xix} Additionally, 85% percent of adults in the U.S. say pharmacists are easy to access.¹⁶

Pharmacies are sometimes the only healthcare provider within reach in some rural and underserved communities and allow for more accessible care for those who may have limited mobility or face transportation challenges, such as seniors. Studies show that Medicare patients visit pharmacies significantly more often than primary care providers – 13 visits per-year compared to seven visits per-year. In rural communities, the difference is more significant – 14 visits compared to five visits annually.^{xx} By providing "Test-and-Treat" services in pharmacies, people can more easily receive timely care. Also, pharmacy-based testing and treatment services streamline access for people to receive both testing and treatment in one place, instead of going to one healthcare location for the test and then to the pharmacy to pick up their treatment.

Myth: Insurance covers healthcare services provided by pharmacists.

Fact: Unlike services provided by other healthcare professionals, clinical services provided by pharmacists, like testing and treatment, are rarely a covered benefit by health plans, despite evidence on the safety and effectiveness of pharmacist-provided care.

Lacking insurance coverage for pharmacist services ultimately limits public access to receive essential and timely care services at their local pharmacy. Importantly, a significant majority of Americans (71%) support insurers paying pharmacists adequately for testing and initiating treatment for various health conditions, recognizing the importance of these services for improved public health, and the need for sustainable reimbursement.

In alignment with the goals of health plans to facilitate cost-effective healthcare, pharmacist-provided clinical services have been proven to reduce downstream, preventable healthcare costs.^{xxi,xxii} Pharmacy interventions provided during the recent public health emergency alone averted more than 1 million deaths, prevented more than 8 million hospitalizations, and saved \$450 billion in healthcare costs.^{xxiii} When it comes to pharmacist testing and treatment for common conditions, early and timely treatment of these conditions can shorten the duration of symptoms and reduce the risk of additional health complications, preventing unnecessary and costly hospitalizations.^{xxiv}

Myth: Pharmacists do not have enough time to offer more services, like testing and treatment.

Fact: Many pharmacists are eager to engage more directly with patients, in fact, a recent survey found that 81% of pharmacists want to expand their clinical services.^{xxv}

Notably, a majority of the respondents said the biggest barrier to offering more clinical services beyond the traditional pharmacy care services is due to the lack of payment for these services – not a lack of capacity to take on additional responsibilities. Also, pharmacies have continued to update their systems and processes, where possible, to free up pharmacists’ time to provide clinical services. This includes shifting more prescription dispensing responsibilities to remote pharmacy teams, utilizing new technology solutions, and leveraging the expertise of pharmacy technicians to perform more tasks that do not require the clinical skills of pharmacists. In fact, research on expanded technician duties, such as final product verification, has demonstrated meaningful opportunity to distribute more pharmacist time to providing more clinical services.^{xxvi, xxvii}

Myth: One-off visits with a pharmacist don’t provide an opportunity for follow-up care nor collaboration with the patient’s other healthcare providers.

Fact: People visit pharmacies 10 times more often than other healthcare providers,²² providing ample opportunities for follow-up care. In published examples of pharmacist testing and treatment, follow up is a common practice, typically within 24-48 hours.^{xxviii, xxix}

Also, when providing testing and treatment services, pharmacies often share information with the patient’s medical provider, if the patient has one. In fact, while the majority of people (60%) use only one pharmacy,^{xxx} the average person sees 18 different doctors in their lifetime^{xxxi} and about 30% of seniors see 5 or more doctors.^{xxxii} Therefore, in some instances, the pharmacy may have the most comprehensive understanding of the patient’s medical picture based on the medications being prescribed by different prescribers. This is especially true because there are documented gaps in communication between specialists and primary care providers.^{xxxiii} In fact, challenges with data interoperability and communication are prevalent across healthcare in general, and are not unique to pharmacy-based care.

Further, research supports pharmacists’ ability to identify health care needs and provide successful referrals and linkage to care when additional care is needed.^{xxxiv, xxxv, xxxvi} For example, in a study of 55 community pharmacies providing testing and treatment for flu, pharmacists performed 75 tests and among them, 8 people (11%) tested positive and were provided appropriate treatment. At the initial visit, 4 patients were instructed to seek additional care based on the pharmacist’s assessment and clinical judgement. These patients were successfully reached at follow-up and reported the following: one diagnosis of pneumonia, one diagnosis of bronchitis, and two antiviral prescriptions for flu. The patients also reported feeling better due to the pharmacist’s referral. In addition, pharmacists successfully followed up with 79% of all tested patients within 48 hours of the initial visit and 78% of those reached reported feeling better.^{xxxvii}

Myth: Pharmacies do not offer the privacy necessary to provide testing and treatment services.

Fact: Pharmacies have long adhered to strict privacy rules required since 2003 under the Health Insurance Portability and Accountability Act (HIPAA) regulations to protect patient health information.

In implementing “test-and-treat” programs, pharmacies ensure that test results and patient assessments are conducted in a private manner and that patient data is securely stored and shared only in accordance with healthcare privacy laws. Increasingly, pharmacies are designating space for private rooms near the pharmacy to conduct patient assessments, tests, vaccinations and other healthcare services. For example, in a study evaluating a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program, patients who completed the 6-month visit survey indicated a high level of satisfaction (>95% very satisfied) with the privacy of conversation with the pharmacist.^{xxxviii}

ⁱ Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. Accreditation Council for Pharmacy Education. February 2015. <https://www.acpe-accredit.org/pdf/Standards2016FINAL.pdf>

ACCREDITATION STANDARDS AND GUIDELINES FOR THE PROFESSIONAL PROGRAM IN PHARMACY LEADING TO THE DOCTOR OF PHARMACY DEGREE. February 2006. <https://www.acpe-accredit.org/pdf/FinalS2007Guidelines2.0.pdf>

ⁱⁱ Competency Statements | North American Pharmacist Licensure Examination. National Association of Boards of Pharmacy.

<https://nabp.pharmacy/programs/examinations/naplex/competency-statements/>

ⁱⁱⁱ Clinical Laboratory Improvement Amendments (CLIA) How to Obtain a CLIA Certificate of Waiver. <https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/howtoobtaincertificateofwaiver.pdf>

^{iv} Klepser ME, Klepser DG, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA. Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness. *Journal of the American Pharmacists Association* (2003). 2016 Jan;56(1):14-21. doi: 10.1016/j.japh.2015.11.008. PMID: 26802915.

^v Grabenstein JD. Essential services: Quantifying the contributions of America's pharmacists in COVID-19 clinical interventions. *Journal of the American Pharmacists Association*. 2022;62(6):1929-1945.e1. doi:https://doi.org/10.1016/j.japh.2022.08.010

^{vi} Zalupski B, Elroumi Z, Klepser DG, Klepser NS, Adams AJ, Klepser ME. Pharmacy-based CLIA-waived testing in the United States: Trends, impact, and the road ahead. *Res Social Adm Pharm*. 2024;20(6):146-151. doi:10.1016/j.sapharm.2024.03.003.

^{vii} Grabenstein JD. Essential services: Quantifying the contributions of America's pharmacists in COVID-19 clinical interventions. *Journal of the American Pharmacists Association*. 2022;62(6):1929-1945.e1. doi:https://doi.org/10.1016/j.japh.2022.08.010

^{viii} Buss VH, Deeks LS, Shield A, Kosari S, Naunton M. Analytical quality and effectiveness of point-of-care testing in community pharmacies: A systematic literature review. *Research in Social and Administrative Pharmacy*. 2019;15(5):483-495. doi:10.1016/j.sapharm.2018.07.013

^{ix} Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G. Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. *Gastroenterol Hepatol (N Y)*. 2017;13(2):98-104.

^x Jakeman B, Gross B, Fortune D, Babb S, Tinker D, Bachrycz A. Evaluation of a pharmacist-performed tuberculosis testing initiative in New Mexico. *Journal of the American Pharmacists Association*. 2015;55(3):307-312. doi:https://doi.org/10.1331/japha.2015.14141

^{xi} Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE. Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. *Research in Social and Administrative Pharmacy*. 2018;14(4):356-359. doi:10.1016/j.sapharm.2017.04.012

^{xii} Klepser DG, Klepser ME, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA. Community pharmacist-physician collaborative streptococcal pharyngitis management program. *Journal of the American Pharmacists Association*. 2016;56(3):323-329.e1. doi:https://doi.org/10.1016/j.japh.2015.11.013

^{xiii} Klepser ME, Adams AJ, Klepser DG. Antimicrobial Stewardship in Outpatient Settings: Leveraging Innovative Physician-Pharmacist Collaborations to Reduce Antibiotic Resistance. *Health Security*. 2015;13(3):166-173. doi:https://doi.org/10.1089/hs.2014.0083

^{xiv} Rebelo A. Wolters Kluwer's Pharmacy Next survey shows 58% of Americans likely to first seek non-emergency healthcare at pharmacies. www.wolterskluwer.com. Published May 17, 2023. <https://www.wolterskluwer.com/en/news/survey-shows-americans-likely-to-first-see-non-emergency-healthcare-at-pharmacies>

^{xv} Morning Consult. Public Support for Pharmacist-Provided Services. Published 2023. <https://www.nacds.org/pdfs/Opinion-Research/NACDS-OpinionResearch-National.pdf>

^{xvi} Kirby J, Mousa N. Evaluating the impact of influenza and streptococcus point-of-care testing and collaborative practice prescribing in a community pharmacy setting. *Journal of the American Pharmacists Association*. 2020;60(3S):S70-S75. doi:https://doi.org/10.1016/j.japh.2020.03.003

^{xvii} Klepser DG, Klepser ME, Smith JK, Dering-Anderson AM, Nelson M, Pohren LE. Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. *Research in Social and Administrative Pharmacy*. 2018;14(4):356-359. doi:10.1016/j.sapharm.2017.04.012

^{xviii} Berenbrok LA, Tang S, Gabriel N, et al. Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. *Journal of the American Pharmacists Association*. 2022;62(6). doi:https://doi.org/10.1016/j.japh.2022.07.003

^{xix} Hemberg N, Huggins D, Michaels N, Moose J. Innovative Community Pharmacy Practice Models in North Carolina. *North Carolina Medical Journal*. 2017;78(3):198-201. doi:https://doi.org/10.18043/ncm.78.3.198

^{xx} Berenbrok LA, Gabriel N, Coley KC, Hernandez I. Evaluation of Frequency of Encounters With Primary Care Physicians vs Visits to Community Pharmacies Among Medicare Beneficiaries. *JAMA Network Open*. 2020;3(7):e209132. doi:https://doi.org/10.1001/jamanetworkopen.2020.9132

^{xxi} Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients' medication adherence and other health outcomes: a systematic review. *International Journal of Pharmacy Practice*. 2018;26(5):387-397. doi:https://doi.org/10.1111/ijpp.12462

^{xxii} Lee JK, Grace KA, Taylor AJ. Effect of a Pharmacy Care Program on Medication Adherence and Persistence, Blood Pressure, and Low-Density Lipoprotein Cholesterol. *JAMA*. 2006;296(21):2563. doi:https://doi.org/10.1001/jama.296.21.joc60162

^{xxiii} Grabenstein JD. Essential services: Quantifying the contributions of America's pharmacists in COVID-19 clinical interventions. *Journal of the American Pharmacists Association*. 2022;62(6):1929-1945.e1. doi:https://doi.org/10.1016/j.japh.2022.08.010

-
- ^{xxxiv} CDC. Influenza antiviral medications: Summary for clinicians. Centers for Disease Control and Prevention. Published December 8, 2023. <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>
- ^{xxxv} Levy S. EnlivenHealth survey finds pharmacists support expanding clinical services, but challenges exist in getting paid. Drug Store News. Published October 19, 2022. <https://drugstorenews.com/enlivenhealth-survey-finds-pharmacists-support-expanding-clinical-services-challenges-exist-getting>
- ^{xxxvi} Andreski M, Myers M, Gainer K, Pudlo A. The Iowa new practice model: Advancing technician roles to increase pharmacists' time to provide patient care services. *Journal of the American Pharmacists Association*. 2018;58(3):268-274.e1. doi:<https://doi.org/10.1016/j.japh.2018.02.005>
- ^{xxxvii} Hohmeier KC, Garst A, Adkins L, Yu X, Desselle SP, Cost M. The Optimizing Care Model: A novel community pharmacy approach to enhance patient care delivery by leveraging the technician workforce through technician product verification. *Journal of the American Pharmacists Association*. 2019;59(6):880-885. doi:<https://doi.org/10.1016/j.japh.2019.07.009>
- ^{xxxviii} Hardin R, Roberts P, Hudspeth B, et al. Development and Implementation of an Influenza Point-Of-Care Testing Service in a Chain Community Pharmacy Setting. *Pharmacy*. 2020;8(4):182. doi:<https://doi.org/10.3390/pharmacy8040182>
- ^{xxxix} Board Authorized Protocols. [pharmacy.ky.gov](https://pharmacy.ky.gov/Pages/Board-Authorized-Protocols.aspx). Published November 8, 2023. <https://pharmacy.ky.gov/Pages/Board-Authorized-Protocols.aspx>
- ^{xl} Marcum ZA, Driessen J, Thorpe CT, Gellad WF, Donohue JM. Impact of Multiple Pharmacy Use on Medication Adherence and Drug-drug Interactions in Older Adults with Medicare Part D. *Journal of the American Geriatrics Society*. 2014;62(2):244-252. doi:<https://doi.org/10.1111/jgs.12645>
- ^{xli} PR Newswire. Survey: Patients See 18.7 Different Doctors on Average. FierceHealthcare. Published April 27, 2010. <https://www.fiercehealthcare.com/healthcare/survey-patients-see-18-7-different-doctors-average>
- ^{xlii} Norton A. Almost 1 in 3 U.S. Seniors Now Sees at Least 5 Doctors Per Year. www.healthday.com. Published November 2, 2021. <https://www.healthday.com/health-news/general-health/11-2-almost-1-in-3-u-s-seniors-now-see-at-least-5-doctors-per-year-2655382216.html>
- ^{xliiii} Timmins L, Kern LM, O'Malley AS, Urato C, Ghosh A, Rich E. Communication Gaps Persist Between Primary Care and Specialist Physicians. *The Annals of Family Medicine*. 2022;20(4):343-347. doi:<https://doi.org/10.1370/afm.2781>
- ^{xliiii} Chen SW, Hochman M, Olayiwola JN, Rubin A. Integration of Pharmacy Teams into Primary Care. The Center for Excellence in Primary Care and the Center for Care Innovations May 2015. https://www.careinnovations.org/wp-content/uploads/2017/10/USC.CEPC_pharm_webinar_FinalV.pdf
- ^{xliiii} Chen SW. Comprehensive Medication Management (CMM) for Hypertension Patients: Driving Value and Sustainability. University of Southern California. <http://betheresandiego.org/storage/files/cmm-for-htn-usc-steven-chen-condensed-slide-deck.pdf>
- ^{xliiii} A Team-based Care Approach to Reach Rural, Underserved Virginia Patients. WWCDPC. 2018. <https://chronicdisease.host/WWCDPC/admin/dompdf/SuccessStories.php?id=712>
- ^{xliiii} Health Quality Innovators. A Partnership in Chronic Care Management. <http://qin.hqi.solutions/wp-content/uploads/2018/05/CCM-poster-with-3-video-QR-link.pdf>
- ^{xliiii} Klepser ME, Klepser DG, Dering-Anderson AM, Morse JA, Smith JK, Klepser SA. Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness. *Journal of the American Pharmacists Association*. 2016;56(1):14-21. doi:<https://doi.org/10.1016/j.japh.2015.11.008>
- ^{xliiii} Havens JP, Scarsi KK, Sayles H, Klepser DG, Swindells S, Bares SH. Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. *Open Forum Infect Dis*. 2019;6(10):ofz365. doi:10.1093/ofid/ofz36